Related Experiment Video
Updated: May 13, 2026

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes
Published on: July 30, 2020
Flurbiprofen-loaded stealth liposomes: studies on the development, characterization, pharmacokinetics, and
My Begum1, K Abbulu, M Sudhakar
1Department of Pharmaceutics, Malla Reddy College of Pharmacy, Maisammaguda, Secunderabad, Andhra Pradesh, India.
Abstract:
Flurbiprofen (FP) is a phenyl alkanoic acid derivative and a family of non-steroidal anti-inflammatory drug used in the treatment of arthritis. The aim of this study was to prepare a new parenteral formulation for FP that can prolong the biologic half-life of the drug, improve its therapeutic efficacy, and reduce its associated side effects targeting the inflammation due to arthritis. PEG-anchored (stealth) and non-PEG-anchored liposomes were prepared by thin film hydration technique followed by extrusion cycle and characterized for in vitro and in vivo. Stealth liposomes (SLs) exhibited increase in percent encapsulation efficiency (68%) and percent drug retention during release studies in 24 h (71%) with good stability for a period of 1 month at -20°C and 4°C (refrigerated temperature) compared with other liposomes. The maximum percent edema inhibition (58%) and significant analgesic effect of 13 s were determined for SLs. The pharmacokinetic parameters after i.v. administration to arthritis induced rats were determined and compared with non-SLs. The marked differences produced for SLs over those of non-SL (conventional) formulations with an increase in area under plasma concentration time curve, t 1/2, mean residence time, and reduced clearance. The drug localization in liver, spleen, and kidney were significantly higher for non-PEGylated liposomes than the SLs. Nearly 3-fold increase in drug concentration was measured in arthritic paw when compared with the other liposome formulations. Thus SLs may help to increase the therapeutic efficacy of FP by increasing the targeting potential at the site of action.
Related Concept Videos
Bioavailability Enhancement: Drug Permeability Enhancement
Modified-Release Drug Delivery Systems: Bioavailability
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Biopharmaceutics and Pharmacokinetics: Overview

